To better illustrate this, Erlotinib was one of the EGFR inhibitors not found to have significantly increased activity in HNSCC cell lines compared with other cancer line types, further emphasizing the importance of accurate drug selection. The gene discussed is EGFR; the disease is head and neck squamous cell carcinoma.